The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Clinical Oncology Next Generation Sequencing Market Research Report 2025
Synopsis
Next generation sequencing (NGS) has created a noteworthy paradigm shift in the clinical diagnostic field. It refers to an aggregate collection of methods in which various sequencing reactions occur at the same time, bringing about vast amounts of sequencing data for a little division of the cost of Sanger sequencing.
The global Clinical Oncology Next Generation Sequencing market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Clinical Oncology Next Generation Sequencing is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Clinical Oncology Next Generation Sequencing is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Clinical Oncology Next Generation Sequencing in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Clinical Oncology Next Generation Sequencing include Illumina, Inc., Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Agilent Technologies, Myriad Genetics, Beijing Genomics Institute (BGI), Perkin Elmer, Foundation Medicine and Pacific Bioscience, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Clinical Oncology Next Generation Sequencing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Clinical Oncology Next Generation Sequencing.
Report Scope
The Clinical Oncology Next Generation Sequencing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Clinical Oncology Next Generation Sequencing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Clinical Oncology Next Generation Sequencing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Illumina, Inc.
Thermo Fisher Scientific
F. Hoffmann-La Roche Ltd.
Agilent Technologies
Myriad Genetics
Beijing Genomics Institute (BGI)
Perkin Elmer
Foundation Medicine
Pacific Bioscience
Oxford Nanopore Technologies Ltd.
Paradigm Diagnostics
Caris Life Sciences
Partek, Inc.
Eurofins Scientific S.E.
Qiagen N.V.
Segment by Type
Whole Genome Sequencing
Whole Exome Sequencing
Targeted Sequencing & Resequencing Centrifuges
Segment by Application
Hospitals
Clinics
Laboratories
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Clinical Oncology Next Generation Sequencing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Next generation sequencing (NGS) has created a noteworthy paradigm shift in the clinical diagnostic field. It refers to an aggregate collection of methods in which various sequencing reactions occur at the same time, bringing about vast amounts of sequencing data for a little division of the cost of Sanger sequencing.
The global Clinical Oncology Next Generation Sequencing market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Clinical Oncology Next Generation Sequencing is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Clinical Oncology Next Generation Sequencing is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Clinical Oncology Next Generation Sequencing in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Clinical Oncology Next Generation Sequencing include Illumina, Inc., Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd., Agilent Technologies, Myriad Genetics, Beijing Genomics Institute (BGI), Perkin Elmer, Foundation Medicine and Pacific Bioscience, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Clinical Oncology Next Generation Sequencing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Clinical Oncology Next Generation Sequencing.
Report Scope
The Clinical Oncology Next Generation Sequencing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Clinical Oncology Next Generation Sequencing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Clinical Oncology Next Generation Sequencing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Illumina, Inc.
Thermo Fisher Scientific
F. Hoffmann-La Roche Ltd.
Agilent Technologies
Myriad Genetics
Beijing Genomics Institute (BGI)
Perkin Elmer
Foundation Medicine
Pacific Bioscience
Oxford Nanopore Technologies Ltd.
Paradigm Diagnostics
Caris Life Sciences
Partek, Inc.
Eurofins Scientific S.E.
Qiagen N.V.
Segment by Type
Whole Genome Sequencing
Whole Exome Sequencing
Targeted Sequencing & Resequencing Centrifuges
Segment by Application
Hospitals
Clinics
Laboratories
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Clinical Oncology Next Generation Sequencing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Clinical Oncology Next Generation Sequencing Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Whole Genome Sequencing
1.2.3 Whole Exome Sequencing
1.2.4 Targeted Sequencing & Resequencing Centrifuges
1.3 Market by Application
1.3.1 Global Clinical Oncology Next Generation Sequencing Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Laboratories
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Clinical Oncology Next Generation Sequencing Market Perspective (2019-2030)
2.2 Clinical Oncology Next Generation Sequencing Growth Trends by Region
2.2.1 Global Clinical Oncology Next Generation Sequencing Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Clinical Oncology Next Generation Sequencing Historic Market Size by Region (2019-2024)
2.2.3 Clinical Oncology Next Generation Sequencing Forecasted Market Size by Region (2025-2030)
2.3 Clinical Oncology Next Generation Sequencing Market Dynamics
2.3.1 Clinical Oncology Next Generation Sequencing Industry Trends
2.3.2 Clinical Oncology Next Generation Sequencing Market Drivers
2.3.3 Clinical Oncology Next Generation Sequencing Market Challenges
2.3.4 Clinical Oncology Next Generation Sequencing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Clinical Oncology Next Generation Sequencing Players by Revenue
3.1.1 Global Top Clinical Oncology Next Generation Sequencing Players by Revenue (2019-2024)
3.1.2 Global Clinical Oncology Next Generation Sequencing Revenue Market Share by Players (2019-2024)
3.2 Global Clinical Oncology Next Generation Sequencing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Clinical Oncology Next Generation Sequencing Revenue
3.4 Global Clinical Oncology Next Generation Sequencing Market Concentration Ratio
3.4.1 Global Clinical Oncology Next Generation Sequencing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Clinical Oncology Next Generation Sequencing Revenue in 2023
3.5 Clinical Oncology Next Generation Sequencing Key Players Head office and Area Served
3.6 Key Players Clinical Oncology Next Generation Sequencing Product Solution and Service
3.7 Date of Enter into Clinical Oncology Next Generation Sequencing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Clinical Oncology Next Generation Sequencing Breakdown Data by Type
4.1 Global Clinical Oncology Next Generation Sequencing Historic Market Size by Type (2019-2024)
4.2 Global Clinical Oncology Next Generation Sequencing Forecasted Market Size by Type (2025-2030)
5 Clinical Oncology Next Generation Sequencing Breakdown Data by Application
5.1 Global Clinical Oncology Next Generation Sequencing Historic Market Size by Application (2019-2024)
5.2 Global Clinical Oncology Next Generation Sequencing Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Clinical Oncology Next Generation Sequencing Market Size (2019-2030)
6.2 North America Clinical Oncology Next Generation Sequencing Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Clinical Oncology Next Generation Sequencing Market Size by Country (2019-2024)
6.4 North America Clinical Oncology Next Generation Sequencing Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Clinical Oncology Next Generation Sequencing Market Size (2019-2030)
7.2 Europe Clinical Oncology Next Generation Sequencing Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Clinical Oncology Next Generation Sequencing Market Size by Country (2019-2024)
7.4 Europe Clinical Oncology Next Generation Sequencing Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Clinical Oncology Next Generation Sequencing Market Size (2019-2030)
8.2 Asia-Pacific Clinical Oncology Next Generation Sequencing Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Clinical Oncology Next Generation Sequencing Market Size by Region (2019-2024)
8.4 Asia-Pacific Clinical Oncology Next Generation Sequencing Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Clinical Oncology Next Generation Sequencing Market Size (2019-2030)
9.2 Latin America Clinical Oncology Next Generation Sequencing Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Clinical Oncology Next Generation Sequencing Market Size by Country (2019-2024)
9.4 Latin America Clinical Oncology Next Generation Sequencing Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Clinical Oncology Next Generation Sequencing Market Size (2019-2030)
10.2 Middle East & Africa Clinical Oncology Next Generation Sequencing Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Clinical Oncology Next Generation Sequencing Market Size by Country (2019-2024)
10.4 Middle East & Africa Clinical Oncology Next Generation Sequencing Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Illumina, Inc.
11.1.1 Illumina, Inc. Company Detail
11.1.2 Illumina, Inc. Business Overview
11.1.3 Illumina, Inc. Clinical Oncology Next Generation Sequencing Introduction
11.1.4 Illumina, Inc. Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024)
11.1.5 Illumina, Inc. Recent Development
11.2 Thermo Fisher Scientific
11.2.1 Thermo Fisher Scientific Company Detail
11.2.2 Thermo Fisher Scientific Business Overview
11.2.3 Thermo Fisher Scientific Clinical Oncology Next Generation Sequencing Introduction
11.2.4 Thermo Fisher Scientific Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024)
11.2.5 Thermo Fisher Scientific Recent Development
11.3 F. Hoffmann-La Roche Ltd.
11.3.1 F. Hoffmann-La Roche Ltd. Company Detail
11.3.2 F. Hoffmann-La Roche Ltd. Business Overview
11.3.3 F. Hoffmann-La Roche Ltd. Clinical Oncology Next Generation Sequencing Introduction
11.3.4 F. Hoffmann-La Roche Ltd. Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024)
11.3.5 F. Hoffmann-La Roche Ltd. Recent Development
11.4 Agilent Technologies
11.4.1 Agilent Technologies Company Detail
11.4.2 Agilent Technologies Business Overview
11.4.3 Agilent Technologies Clinical Oncology Next Generation Sequencing Introduction
11.4.4 Agilent Technologies Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024)
11.4.5 Agilent Technologies Recent Development
11.5 Myriad Genetics
11.5.1 Myriad Genetics Company Detail
11.5.2 Myriad Genetics Business Overview
11.5.3 Myriad Genetics Clinical Oncology Next Generation Sequencing Introduction
11.5.4 Myriad Genetics Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024)
11.5.5 Myriad Genetics Recent Development
11.6 Beijing Genomics Institute (BGI)
11.6.1 Beijing Genomics Institute (BGI) Company Detail
11.6.2 Beijing Genomics Institute (BGI) Business Overview
11.6.3 Beijing Genomics Institute (BGI) Clinical Oncology Next Generation Sequencing Introduction
11.6.4 Beijing Genomics Institute (BGI) Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024)
11.6.5 Beijing Genomics Institute (BGI) Recent Development
11.7 Perkin Elmer
11.7.1 Perkin Elmer Company Detail
11.7.2 Perkin Elmer Business Overview
11.7.3 Perkin Elmer Clinical Oncology Next Generation Sequencing Introduction
11.7.4 Perkin Elmer Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024)
11.7.5 Perkin Elmer Recent Development
11.8 Foundation Medicine
11.8.1 Foundation Medicine Company Detail
11.8.2 Foundation Medicine Business Overview
11.8.3 Foundation Medicine Clinical Oncology Next Generation Sequencing Introduction
11.8.4 Foundation Medicine Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024)
11.8.5 Foundation Medicine Recent Development
11.9 Pacific Bioscience
11.9.1 Pacific Bioscience Company Detail
11.9.2 Pacific Bioscience Business Overview
11.9.3 Pacific Bioscience Clinical Oncology Next Generation Sequencing Introduction
11.9.4 Pacific Bioscience Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024)
11.9.5 Pacific Bioscience Recent Development
11.10 Oxford Nanopore Technologies Ltd.
11.10.1 Oxford Nanopore Technologies Ltd. Company Detail
11.10.2 Oxford Nanopore Technologies Ltd. Business Overview
11.10.3 Oxford Nanopore Technologies Ltd. Clinical Oncology Next Generation Sequencing Introduction
11.10.4 Oxford Nanopore Technologies Ltd. Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024)
11.10.5 Oxford Nanopore Technologies Ltd. Recent Development
11.11 Paradigm Diagnostics
11.11.1 Paradigm Diagnostics Company Detail
11.11.2 Paradigm Diagnostics Business Overview
11.11.3 Paradigm Diagnostics Clinical Oncology Next Generation Sequencing Introduction
11.11.4 Paradigm Diagnostics Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024)
11.11.5 Paradigm Diagnostics Recent Development
11.12 Caris Life Sciences
11.12.1 Caris Life Sciences Company Detail
11.12.2 Caris Life Sciences Business Overview
11.12.3 Caris Life Sciences Clinical Oncology Next Generation Sequencing Introduction
11.12.4 Caris Life Sciences Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024)
11.12.5 Caris Life Sciences Recent Development
11.13 Partek, Inc.
11.13.1 Partek, Inc. Company Detail
11.13.2 Partek, Inc. Business Overview
11.13.3 Partek, Inc. Clinical Oncology Next Generation Sequencing Introduction
11.13.4 Partek, Inc. Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024)
11.13.5 Partek, Inc. Recent Development
11.14 Eurofins Scientific S.E.
11.14.1 Eurofins Scientific S.E. Company Detail
11.14.2 Eurofins Scientific S.E. Business Overview
11.14.3 Eurofins Scientific S.E. Clinical Oncology Next Generation Sequencing Introduction
11.14.4 Eurofins Scientific S.E. Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024)
11.14.5 Eurofins Scientific S.E. Recent Development
11.15 Qiagen N.V.
11.15.1 Qiagen N.V. Company Detail
11.15.2 Qiagen N.V. Business Overview
11.15.3 Qiagen N.V. Clinical Oncology Next Generation Sequencing Introduction
11.15.4 Qiagen N.V. Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024)
11.15.5 Qiagen N.V. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Clinical Oncology Next Generation Sequencing Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Whole Genome Sequencing
Table 3. Key Players of Whole Exome Sequencing
Table 4. Key Players of Targeted Sequencing & Resequencing Centrifuges
Table 5. Global Clinical Oncology Next Generation Sequencing Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Clinical Oncology Next Generation Sequencing Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Clinical Oncology Next Generation Sequencing Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Clinical Oncology Next Generation Sequencing Market Share by Region (2019-2024)
Table 9. Global Clinical Oncology Next Generation Sequencing Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Clinical Oncology Next Generation Sequencing Market Share by Region (2025-2030)
Table 11. Clinical Oncology Next Generation Sequencing Market Trends
Table 12. Clinical Oncology Next Generation Sequencing Market Drivers
Table 13. Clinical Oncology Next Generation Sequencing Market Challenges
Table 14. Clinical Oncology Next Generation Sequencing Market Restraints
Table 15. Global Clinical Oncology Next Generation Sequencing Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Clinical Oncology Next Generation Sequencing Market Share by Players (2019-2024)
Table 17. Global Top Clinical Oncology Next Generation Sequencing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Clinical Oncology Next Generation Sequencing as of 2023)
Table 18. Ranking of Global Top Clinical Oncology Next Generation Sequencing Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Clinical Oncology Next Generation Sequencing Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Clinical Oncology Next Generation Sequencing Product Solution and Service
Table 22. Date of Enter into Clinical Oncology Next Generation Sequencing Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Clinical Oncology Next Generation Sequencing Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Clinical Oncology Next Generation Sequencing Revenue Market Share by Type (2019-2024)
Table 26. Global Clinical Oncology Next Generation Sequencing Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Clinical Oncology Next Generation Sequencing Revenue Market Share by Type (2025-2030)
Table 28. Global Clinical Oncology Next Generation Sequencing Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Clinical Oncology Next Generation Sequencing Revenue Market Share by Application (2019-2024)
Table 30. Global Clinical Oncology Next Generation Sequencing Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Clinical Oncology Next Generation Sequencing Revenue Market Share by Application (2025-2030)
Table 32. North America Clinical Oncology Next Generation Sequencing Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Clinical Oncology Next Generation Sequencing Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Clinical Oncology Next Generation Sequencing Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Clinical Oncology Next Generation Sequencing Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Clinical Oncology Next Generation Sequencing Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Clinical Oncology Next Generation Sequencing Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Clinical Oncology Next Generation Sequencing Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Clinical Oncology Next Generation Sequencing Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Clinical Oncology Next Generation Sequencing Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Clinical Oncology Next Generation Sequencing Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Clinical Oncology Next Generation Sequencing Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Clinical Oncology Next Generation Sequencing Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Clinical Oncology Next Generation Sequencing Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Clinical Oncology Next Generation Sequencing Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Clinical Oncology Next Generation Sequencing Market Size by Country (2025-2030) & (US$ Million)
Table 47. Illumina, Inc. Company Detail
Table 48. Illumina, Inc. Business Overview
Table 49. Illumina, Inc. Clinical Oncology Next Generation Sequencing Product
Table 50. Illumina, Inc. Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024) & (US$ Million)
Table 51. Illumina, Inc. Recent Development
Table 52. Thermo Fisher Scientific Company Detail
Table 53. Thermo Fisher Scientific Business Overview
Table 54. Thermo Fisher Scientific Clinical Oncology Next Generation Sequencing Product
Table 55. Thermo Fisher Scientific Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024) & (US$ Million)
Table 56. Thermo Fisher Scientific Recent Development
Table 57. F. Hoffmann-La Roche Ltd. Company Detail
Table 58. F. Hoffmann-La Roche Ltd. Business Overview
Table 59. F. Hoffmann-La Roche Ltd. Clinical Oncology Next Generation Sequencing Product
Table 60. F. Hoffmann-La Roche Ltd. Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024) & (US$ Million)
Table 61. F. Hoffmann-La Roche Ltd. Recent Development
Table 62. Agilent Technologies Company Detail
Table 63. Agilent Technologies Business Overview
Table 64. Agilent Technologies Clinical Oncology Next Generation Sequencing Product
Table 65. Agilent Technologies Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024) & (US$ Million)
Table 66. Agilent Technologies Recent Development
Table 67. Myriad Genetics Company Detail
Table 68. Myriad Genetics Business Overview
Table 69. Myriad Genetics Clinical Oncology Next Generation Sequencing Product
Table 70. Myriad Genetics Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024) & (US$ Million)
Table 71. Myriad Genetics Recent Development
Table 72. Beijing Genomics Institute (BGI) Company Detail
Table 73. Beijing Genomics Institute (BGI) Business Overview
Table 74. Beijing Genomics Institute (BGI) Clinical Oncology Next Generation Sequencing Product
Table 75. Beijing Genomics Institute (BGI) Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024) & (US$ Million)
Table 76. Beijing Genomics Institute (BGI) Recent Development
Table 77. Perkin Elmer Company Detail
Table 78. Perkin Elmer Business Overview
Table 79. Perkin Elmer Clinical Oncology Next Generation Sequencing Product
Table 80. Perkin Elmer Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024) & (US$ Million)
Table 81. Perkin Elmer Recent Development
Table 82. Foundation Medicine Company Detail
Table 83. Foundation Medicine Business Overview
Table 84. Foundation Medicine Clinical Oncology Next Generation Sequencing Product
Table 85. Foundation Medicine Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024) & (US$ Million)
Table 86. Foundation Medicine Recent Development
Table 87. Pacific Bioscience Company Detail
Table 88. Pacific Bioscience Business Overview
Table 89. Pacific Bioscience Clinical Oncology Next Generation Sequencing Product
Table 90. Pacific Bioscience Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024) & (US$ Million)
Table 91. Pacific Bioscience Recent Development
Table 92. Oxford Nanopore Technologies Ltd. Company Detail
Table 93. Oxford Nanopore Technologies Ltd. Business Overview
Table 94. Oxford Nanopore Technologies Ltd. Clinical Oncology Next Generation Sequencing Product
Table 95. Oxford Nanopore Technologies Ltd. Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024) & (US$ Million)
Table 96. Oxford Nanopore Technologies Ltd. Recent Development
Table 97. Paradigm Diagnostics Company Detail
Table 98. Paradigm Diagnostics Business Overview
Table 99. Paradigm Diagnostics Clinical Oncology Next Generation Sequencing Product
Table 100. Paradigm Diagnostics Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024) & (US$ Million)
Table 101. Paradigm Diagnostics Recent Development
Table 102. Caris Life Sciences Company Detail
Table 103. Caris Life Sciences Business Overview
Table 104. Caris Life Sciences Clinical Oncology Next Generation Sequencing Product
Table 105. Caris Life Sciences Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024) & (US$ Million)
Table 106. Caris Life Sciences Recent Development
Table 107. Partek, Inc. Company Detail
Table 108. Partek, Inc. Business Overview
Table 109. Partek, Inc. Clinical Oncology Next Generation Sequencing Product
Table 110. Partek, Inc. Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024) & (US$ Million)
Table 111. Partek, Inc. Recent Development
Table 112. Eurofins Scientific S.E. Company Detail
Table 113. Eurofins Scientific S.E. Business Overview
Table 114. Eurofins Scientific S.E. Clinical Oncology Next Generation Sequencing Product
Table 115. Eurofins Scientific S.E. Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024) & (US$ Million)
Table 116. Eurofins Scientific S.E. Recent Development
Table 117. Qiagen N.V. Company Detail
Table 118. Qiagen N.V. Business Overview
Table 119. Qiagen N.V. Clinical Oncology Next Generation Sequencing Product
Table 120. Qiagen N.V. Revenue in Clinical Oncology Next Generation Sequencing Business (2019-2024) & (US$ Million)
Table 121. Qiagen N.V. Recent Development
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Clinical Oncology Next Generation Sequencing Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Clinical Oncology Next Generation Sequencing Market Share by Type: 2023 VS 2030
Figure 3. Whole Genome Sequencing Features
Figure 4. Whole Exome Sequencing Features
Figure 5. Targeted Sequencing & Resequencing Centrifuges Features
Figure 6. Global Clinical Oncology Next Generation Sequencing Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Clinical Oncology Next Generation Sequencing Market Share by Application: 2023 VS 2030
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Laboratories Case Studies
Figure 11. Clinical Oncology Next Generation Sequencing Report Years Considered
Figure 12. Global Clinical Oncology Next Generation Sequencing Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Clinical Oncology Next Generation Sequencing Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Clinical Oncology Next Generation Sequencing Market Share by Region: 2023 VS 2030
Figure 15. Global Clinical Oncology Next Generation Sequencing Market Share by Players in 2023
Figure 16. Global Top Clinical Oncology Next Generation Sequencing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Clinical Oncology Next Generation Sequencing as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Clinical Oncology Next Generation Sequencing Revenue in 2023
Figure 18. North America Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Clinical Oncology Next Generation Sequencing Market Share by Country (2019-2030)
Figure 20. United States Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Clinical Oncology Next Generation Sequencing Market Share by Country (2019-2030)
Figure 24. Germany Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Clinical Oncology Next Generation Sequencing Market Share by Region (2019-2030)
Figure 32. China Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Clinical Oncology Next Generation Sequencing Market Share by Country (2019-2030)
Figure 40. Mexico Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Clinical Oncology Next Generation Sequencing Market Share by Country (2019-2030)
Figure 44. Turkey Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Clinical Oncology Next Generation Sequencing Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Illumina, Inc. Revenue Growth Rate in Clinical Oncology Next Generation Sequencing Business (2019-2024)
Figure 47. Thermo Fisher Scientific Revenue Growth Rate in Clinical Oncology Next Generation Sequencing Business (2019-2024)
Figure 48. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Clinical Oncology Next Generation Sequencing Business (2019-2024)
Figure 49. Agilent Technologies Revenue Growth Rate in Clinical Oncology Next Generation Sequencing Business (2019-2024)
Figure 50. Myriad Genetics Revenue Growth Rate in Clinical Oncology Next Generation Sequencing Business (2019-2024)
Figure 51. Beijing Genomics Institute (BGI) Revenue Growth Rate in Clinical Oncology Next Generation Sequencing Business (2019-2024)
Figure 52. Perkin Elmer Revenue Growth Rate in Clinical Oncology Next Generation Sequencing Business (2019-2024)
Figure 53. Foundation Medicine Revenue Growth Rate in Clinical Oncology Next Generation Sequencing Business (2019-2024)
Figure 54. Pacific Bioscience Revenue Growth Rate in Clinical Oncology Next Generation Sequencing Business (2019-2024)
Figure 55. Oxford Nanopore Technologies Ltd. Revenue Growth Rate in Clinical Oncology Next Generation Sequencing Business (2019-2024)
Figure 56. Paradigm Diagnostics Revenue Growth Rate in Clinical Oncology Next Generation Sequencing Business (2019-2024)
Figure 57. Caris Life Sciences Revenue Growth Rate in Clinical Oncology Next Generation Sequencing Business (2019-2024)
Figure 58. Partek, Inc. Revenue Growth Rate in Clinical Oncology Next Generation Sequencing Business (2019-2024)
Figure 59. Eurofins Scientific S.E. Revenue Growth Rate in Clinical Oncology Next Generation Sequencing Business (2019-2024)
Figure 60. Qiagen N.V. Revenue Growth Rate in Clinical Oncology Next Generation Sequencing Business (2019-2024)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
